Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia-Reference-Cited by-同舟云学术

Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia

Published:2020-03-16 Issue:7 Volume:86 Page:1367-1376
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Kuruvilla Denison¹,Chia Yen Lin¹,Balic Kemal¹,Yao Nai Shun²,Kreitman Robert J.³,Pastan Ira³,Li Xia²,Standifer Nathan¹,Liang Meina¹,Tseng Chih‐Ming¹,Faggioni Raffaella¹,Roskos Lorin²

Affiliation:

1. AstraZeneca South San Francisco CA USA

2. AstraZeneca Gaithersburg MD USA

3. National Cancer Institute, National Institutes of Health Bethesda MD USA

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14250

Reference22 articles.

1. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

2. Leukemic Reticuloendotheliosis

3. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

4. Hairy cell leukemia

5. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14

2. Immunotherapy;Medicines for Cancer;2023

3. Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective;Antibody Therapeutics;2022-06-16

4. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors;Blood;2022-04-14

5. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues;Blood Reviews;2022-01